nach oben

Inflammopharmacology

Erschienen in:

16.07.2019 | Original Article

Cysteinyl leukotriene receptor antagonism: a promising pharmacological strategy for lowering the severity of arthritis

verfasst von: Nayana Venugopal, Pooja Acharya, Mehrdad Zarei, Ramaprasad Ravichandra Talahalli

Erschienen in: Inflammopharmacology | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Background and aims

Though cyclooxygenase inhibitors are employed in rheumatoid arthritis treatment, modulators of leukotrienes are underexplored. We investigated the therapeutic potential of montelukast, a known cysteinyl leukotriene receptor-1 (CysLT1) inhibitor in an experimental rat model of arthritis.

Methods

Arthritis was induced in rats, and montelukast (5 mg/kg body wt.) was administered prophylactically (PAM) and therapeutically (TAM) through oral route.

Results and discussion

Blood and joint tissue markers of oxidative stress (lipid peroxidation, protein carbonyls, and nitric oxides) were significantly (p < 0.05) reduced in montelukast administered rats. Paw inflammation, RA markers (RF and CRP), eicosanoids (PGE₂, LTB₄, and LTC₄), cytokines (IL-1β and MCP-1), activity of hydrolytic enzymes (collagenase, elastase, and hyaluronidase), expression of matrix metalloproteinases (MMP), and EP-4 receptor were significantly (p < 0.05) reduced in montelukast administered rats. This study established that leukotriene inhibition through montelukast lowered the severity of arthritis and thus a potential strategy for reducing the severity of arthritis.

Graphic abstract

Abramson SB, Amin A (2002) Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology 41(9):972–980CrossRef

Bieth J, Spiess B, Wermuth CG (1974) The synthesis and analytical use of a highly sensitive and convenient substrate of elastase. Biochem Med 11(4):350–357CrossRef

Bosnjak B, Stelzmueller B, Erb KJ, Epstein MM (2011) Treatment of allergic asthma: modulation of Th2 cells and their responses. Respir Res 12(1):114CrossRef

Bousquet J, Demoly P, Humbert M (2009) Montelukast in guidelines and beyond. Adv Ther 26(6):575–587CrossRef

Brand D, Latham KA, Rosloniec EF (2007) Collagen-induced arthritis. Nat Protoc 2(5):1269–1275CrossRef

Bray MA, Cunningham FM, Ford-Hutchinson AW, Smith MJ (1981) Leukotriene B4: a mediator of vascular permeability. Br J Pharmacol 72(3):483–486CrossRef

Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R (2003) Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta 32(1–2):23–38CrossRef

Goronzy JJ, Weyand CM (2009) Developments in the scientific understanding of rheumatoid arthritis. Arthritis Res Ther 11(5):249CrossRef

Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR (1982) Analysis of nitrate, nitrite and [¹⁵N] nitrate in biological fluids. Anal Biochem 126(1):131–138CrossRef

Gruenwald J, Graubaum HJ, Hansen K, Grube B (2004) Efficacy and tolerability of a combination of lyprinol and high concentrations of EPA and DHA in inflammatory rheumatoid disorders. Adv Ther 21(3):197–201CrossRef

Gubitosi-Klug RA, Talahalli R, Du Y, Nadler JL, Kern TS (2008) 5-Lipoxygenase, but not 12/15-lipoxygenase, contributes to degeneration of retinal capillaries in a mouse model of diabetic retinopathy. Diabetes 57(5):1387–1393CrossRef

Hamid Q, Tulic MK, Liu MC, Moqbel R (2003) Inflammatory cells in asthma: mechanisms and implications for therapy. J Aller Clin Immunol 111(1):S5–S17CrossRef

Honda T, Segi-Nishida E, Miyachi Y, Narumiya S (2006) Prostacyclin-IP signaling and prostaglandin E2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis. J Exp Med 203(2):325–335CrossRef

Kahlenberg JM, Fox DA (2011) Advances in the medical treatment of rheumatoid arthritis. Hand Clin 27(1):11–20CrossRef

Kang JH, Lim H, Yim DSM (2018) Montelukast inhibits RANKL-induced osteoclast formation and bone loss via CysLTR1 and P2Y12. Mol Med Rep 18(2):2387–2398PubMed

Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF, Williams GR, Becker JC, Hagerty DT, Moreland LW (2003) Treatment of rheumatoid arthritis by selective inhibition of T cell activation with fusion protein CTLA4Ig. N Engl J Med 349(20):1907–1915CrossRef

Lin CR, Amaya F, Barrett L, Wang H, Takada J, Samad TA, Woolf CJ (2006) Prostaglandin E2 receptor EP4 contributes to inflammatory pain hypersensitivity. J Pharmacol Exp Ther 319(3):1096–1103CrossRef

Lokesh BR, Hsieh HL, Kinsella JE (1986) Alterations in the lipids and prostaglandins in mouse spleen following the ingestion of menhaden oil. Ann Nutr Metab 30(6):357–364CrossRef

Martel-Pelletier J, Pelletier JP, Fahmi H (2003) Cyclooxygenase-2 and prostaglandins in articular tissues. Semin Arthritis Rheum 33(3):155–167CrossRef

Mathews MB, Dorfman A (1955) Inhibition of hyaluronidase. Physiol Rev 35(2):381–402CrossRef

McInnes IB, Schet G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365(23):2205–2219CrossRef

Mesquita CS, Oliveira R, Bento F, Geraldo D, Rodrigues JV, Marcos JC (2014) Simplified 2, 4-dinitrophenylhydrazine spectrophotometric assay for quantification of carbonyls in oxidized proteins. Anal Biochem 458:69–71CrossRef

Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95(2):351–358CrossRef

Ong CK, Lirk P, Tan CH, Seymour RA (2007) An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin Med Res 5(1):19–34CrossRef

Sakurai H, Kohsaka H, Liu MF, Higashiyama H, Hirata Y, Kanno K, Saito I, Miyasaka N (1995) Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides. J Clin Invest 96(5):2357–2363CrossRef

Schett G, Gravallese E (2012) Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol 8(11):656–664CrossRef

Shah R, Raska KJr, Tiku ML (2005) The presence of molecular markers of in vivo lipid peroxidation in osteoarthritic cartilage: a pathogenic role in osteoarthritis. Arthritis Rheum 52(9):2799–2807CrossRef

Shaw T, Quan J, Totoritis M (2003) B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Ann Rheum Dis 62(2):55–59

Sheibanie AF, Khayrullina T, Safadi FF, Ganea D (2007) Prostaglandin E2 exacerbates collagen-induced arthritis in mice through the inflammatory interleukin-23/interleukin-17 axis. Arthritis Rheum 56(8):2608–2619CrossRef

Sprague AH, Khalil RA (2009) Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol 78(6):539–552CrossRef

Van Wart HE, Steinbrink DR (1981) A continuous spectrophotometric assay for clostridium histolyticum collagenase. Anal Biochem 113(2):356–365CrossRef

Vijaykumar M, Sambaiah K, Lokesh BR (1999) The anhydrous milk fat lowers serum prostaglandins and secretion of leukotrienes by rat peritoneal macrophages. Prostaglandins Leukot Essent Fatty Acids 61(4):249–254CrossRef

Titel: Cysteinyl leukotriene receptor antagonism: a promising pharmacological strategy for lowering the severity of arthritis
verfasst von: Nayana Venugopal
Pooja Acharya
Mehrdad Zarei
Ramaprasad Ravichandra Talahalli
Publikationsdatum: 16.07.2019
Verlag: Springer International Publishing
Erschienen in: Inflammopharmacology / Ausgabe 5/2019
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-019-00618-0

Springer Medizin

Abstract

Background and aims

Methods

Results and discussion

Graphic abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2019

International multicenter randomized, placebo-controlled phase III clinical trial of β-d-mannuronic acid in rheumatoid arthritis patients

Naringenin inhibits migration of breast cancer cells via inflammatory and apoptosis cell signaling pathways

Curcumin: a modulator of inflammatory signaling pathways in the immune system

Anti-inflammatory role of TPCA-1 encapsulated nanosomes in porcine chondrocytes against TNF-α stimulation

Identification of bioactive phenolics from Porana sinensis Hemsl. stem by UPLC-QTOF-MS/MS and the confirmation of anti-inflammatory indicators using LPS-induced RAW264.7 cells

Sumatriptan protects against myocardial ischaemia–reperfusion injury by inhibition of inflammation in rat model